Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Adv Ther · 2019 · PMC6822860 · PMID 31140123

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

For EFS, the ITC analyses indicated a favorable trend for InO compared with Blina (Supplementary Table 2; Fig. 1 ; see TOWER study Fig. 1c [ 11 ]).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.